+

RU2018107695A - Заряженные блокаторы ионных каналов и способы их применения - Google Patents

Заряженные блокаторы ионных каналов и способы их применения Download PDF

Info

Publication number
RU2018107695A
RU2018107695A RU2018107695A RU2018107695A RU2018107695A RU 2018107695 A RU2018107695 A RU 2018107695A RU 2018107695 A RU2018107695 A RU 2018107695A RU 2018107695 A RU2018107695 A RU 2018107695A RU 2018107695 A RU2018107695 A RU 2018107695A
Authority
RU
Russia
Prior art keywords
compound
alkyl
independently selected
alkynyl
alkenyl
Prior art date
Application number
RU2018107695A
Other languages
English (en)
Other versions
RU2018107695A3 (ru
Inventor
Брюс П. БИН
Клиффорд Дж. ВУЛФ
Дзинбо ЛИ
Сооиеон ДЗО
Дэвид РОБЕРСОН
Себастьен ТАЛЬБО
Original Assignee
Президент Энд Феллоуз Оф Гарвард Колледж
Чилдрен'З Медикал Сентер Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Президент Энд Феллоуз Оф Гарвард Колледж, Чилдрен'З Медикал Сентер Корпорейшн filed Critical Президент Энд Феллоуз Оф Гарвард Колледж
Publication of RU2018107695A publication Critical patent/RU2018107695A/ru
Publication of RU2018107695A3 publication Critical patent/RU2018107695A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/037—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements with quaternary ring nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)

Claims (54)

1. Четвертичное аминное соединение, имеющее формулу (I)
Figure 00000001
где
R1F и R1G вместе образуют гетероциклическое кольцо, имеющее по меньшей мере один атом азота; и где
каждый из R1A, R1B, и R1C независимо выбран из H, галогена, C1-4 алкила, C2-4 алкенила, C2-4 алкинила, OR1I, NR1JR1K, NR1LC(O)R1M, S(O)R1N, SO2R1OR1P, SO2NR1QR1R, SO3R1S, CO2R1T, C(O)R1U и C(O)NR1VR1W; и каждый из R1I, R1J, R1K, R1L, R1M, R1N, R1O, R1P, R1Q, R1R, R1S, R1T, R1U, R1V и R1W независимо выбран из H, C1-4 алкила, C2-4 алкенила, C2-4 алкинила и C2-4 гетероалкила; где
X1 выбран из -CR1XR1Y-, -NR1ZC(O)-, -OC(O)-, -SC(O)-, -C(O)NR1AA-, -CO2- и -OC(S)-; и каждый из R1X, R1Y, R1Z и R1AA независимо выбран из H, C1-4 алкила, C2-4 алкенила, C2-4 алкинила, и C2-4 гетероалкила; где
каждый из R1D и R1E независимо выбран из H, C1-4 алкила, C2-4 алкенила, C2-4 алкинила, C2-4 гетероалкила, необязательно замещенного галогеном, C3-8 циклическим алкилом, арилом или гетероарилом, и C3-6 циклоалкила или R1D и R1E вместе образуют 3-6-членное гетероциклическое или гетероалкильное кольцо; и где
R1H выбран из C1-4 алкила, C2-4 алкенила, C2-4 алкинила, C2-4 гетероалкила, необязательно замещенного галогеном, C3-8 циклическим алкилом, арилом или гетероарилом, и C3-6 циклоалкила.
2. Соединение по п.1, где X1 представляет собой -NHC(O)-.
3. Соединение по п.1 или 2, где каждый из R1A и R1B независимо выбран из H, галогена, C1-4 алкила, C2-4 алкенила, C2-4 алкинила и NR1JR1K; и каждый из R1J и R1K независимо выбран из H, C1-4 алкила, C2-4 алкенила, C2-4 алкинила и C2-4 гетероалкила; или где по меньшей мере один R1C присутствует.
4. Соединение по любому из пп. 1-3, где R1D представляет собой C1-4 алкил, необязательно замещенный галогеном, C3-8 циклическим алкилом, арилом или гетероарилом.
5. Соединение по любому из пп. 1-4, где R1E представляет собой H или C1-4 алкил, необязательно замещенный галогеном, C3-8 циклическим алкилом, арилом или гетероарилом.
6. Соединение по любому из пп. 1-5, где R1H представляет собой C1-4 алкил, необязательно замещенный галогеном, C3-8 циклическим алкилом, арилом или гетероарилом.
7. Соединение по любому из пп. 1-6, где указанное соединение представляет собой соединение в таблице 1.
8. Соединение по п.7, где указанное соединение представляет собой
Figure 00000002
(Соединение 6).
9. Соединение по п.7, где указанное соединение представляет собой
Figure 00000003
(Соединение 3).
10. Четвертичное аминное соединение, имеющее формулу (II)
Figure 00000004
где m равен 0 или 1; где
каждый из R2A, R2B, и R2C, независимо выбран из H, галогена, C1-4 алкила, C2-4 алкенила, C2-4 алкинила, CF3, OR2H, NR2IR2J, NR2KC(O)R2L, S(O)R2M, SO2R2NR2O, SO2NR2PR2Q, SO3R2R, CO2R2S, C(O)R2T, и C(O)NR2UR2V; и каждый из R2H, R2I, R2J, R2K, R2L, R2M, R2N, R2O, R2P, R2Q, R2R, R2S, R2T, R2U и R2V независимо выбран из H, C1-4 алкила, C2-4 алкенила, C2-4 алкинила и C2-4 гетероалкила; где
n равен 0, 1, 2, 3, 4, 5, 6, 7, 8 или 9 и каждый R2F независимо выбран из галогена, C1-4 алкила, C2-4 алкенила, C2-4 алкинила, CF3, OR2H, NR2IR2J, NR2KC(O)R2L, S(O)R2M, SO2R2NR2O, SO2NR2PR2Q, SO3R2R, CO2R2S, C(O)R2T и C(O)NR2UR2V; и каждый из R2H, R2I, R2J, R2K, R2L, R2M, R2N, R2O, R2P, R2Q, R2R, R2S, R2T, R2U и R2V независимо выбран из H, C1-4 алкила, C2-4 алкенила, C2-4 алкинила и C2-4 гетероалкила; и где
каждый из R2D и R2E независимо выбран из C1-4 алкила, C2-4 алкенила, C2-4 алкинила, C2-4 гетероалкила, необязательно замещенного галогеном, циклическим алкилом, арилом или гетероарилом, и C3-6 циклоалкила.
11. Соединение по п.10, где каждый из R2D и R2E представляет собой C1-4 алкил, необязательно замещенный галогеном, циклическим алкилом, арилом или гетероарилом.
12. Соединение по п.10 или 11, где каждый из R2A, R2B и R2C независимо выбран из H, галогена, C1-4 алкила и CF3; или где по меньшей мере один R2C присутствует; или где по меньшей мере один R2F присутствует.
13. Соединение по любому из пп. 10-12, где указанное соединение представляет собой соединение в таблице 2.
14. Соединение по п.13, где указанное соединение представляет собой
Figure 00000005
(Соединение 14).
15. Четвертичное аминное соединение, имеющее общую формулу (III)
Figure 00000006
где n равен 0, 1, 2, или 3; где
каждый из R3A, R3B, и R3C независимо выбран из H, галогена, C1-4 алкила, C2-4 алкенила, C2-4 алкинила, OR3I, NR3JR3K, NR3LC(O)R3M, S(O)R3N, SO2R3OR3P, SO2NR3QR3R, SO3R3S, CO2R3T, C(O)R3U и C(O)NR3VR3W; и каждый из R3I, R3J, R3K, R3L, R3M, R3N, R3O, R3P, R3Q, R3R, R3S, R3T, R3U, R3V и R3W независимо выбран из H, C1-4 алкила, C2-4 алкенила, C2-4 алкинила и C2-4 гетероалкила; где
X3 выбран из -NHC(O)- и -C(O)NH; где
каждый из R3D и R3E могут быть независимо выбраны из H, C1-4 алкила, C2-4 алкенила, C2-4 алкинила, C2-4 гетероалкила, необязательно замещенного галогеном, циклическим алкилом, арилом или гетероарилом, и C3-6 циклоалкила, или R1D и R1E вместе могут образовывать 3-6-членное гетероциклическое или гетероалкильное кольцо; и где
каждый из R3F, R3G, и R3H независимо выбран из C1-4 алкила, C2-4 алкенила, C2-4 алкинила, C2-4 гетероалкила, необязательно замещенного галогеном, циклическим алкилом, арилом или гетероарилом, и C3-6 циклоалкила
16. Соединение по п.15, где X3 представляет собой -NHC(O)-.
17. Соединение по п.15 или 16, где n равно 0 или 1.
18. Соединение по любому из пп. 15-17, где каждый из R3A, R3B и R3C независимо выбран из H, C1-4 алкила и NR3JR3K; и каждый из R3J и R3K независимо выбран из H, C1-4 алкила, C2-4 алкенила, C2-4 алкинила и C2-4 гетероалкила.
19. Соединение по любому из пп. 15-18, где каждый из R3E, R3F и R3G независимо выбран из C1-4 алкила, необязательно замещенного галогеном, циклическим алкилом, арилом или гетероарилом, и C3-6 циклоалкила.
20. Соединение по любому из пп. 15-19, где указанное соединение представляет собой любое из соединений No 21-24 в таблице 3.
21. Соединение по любому из пп.15-20, где указанное соединение представляет собой
Figure 00000007
(Соединение 21).
22. Композиция, содержащая четвертичное аминное соединение по любому из пп.1-21 и фармацевтически приемлемый эксципиент.
23. Соединение по п.21, где указанная композиция составлена для перорального, внутривенного, внутримышечного, ректального, кожного, подкожного, местного, трансдермального, подъязычного, назального, ингаляционного, вагинального, интратекального, эпидурального или глазного введения.
24. Способ лечения боли, зуда или нейрогенного воспалительного заболевания у пациента, указанный способ включает введение указанному пациенту композиции, содержащей четвертичное аминное соединение по любому из пп.1-21, где указанное соединение ингибирует один или несколько потенциалзависимых ионных каналов, присутствующих в ноцицепторах и/или прурицепторах при нанесении на внутреннюю поверхность указанных каналов, но по существу не ингибируют указанные каналы при нанесении на внешнюю поверхность указанных каналов, и где указанное соединение способно проникать в ноцицепторы или прурицепторы через каналообразующий рецептор, когда указанный рецептор активирован и ингибирует упомянутый один или несколько потенциалзависимых ионных каналов, присутствующих в указанных ноцицепторах.
25. Способ по п.24, где указанный каналообразующий рецептор представляет собой ионный канал, действующий по механизму транзиторного рецепторного потенциала (TRP-каналообразующий рецептор)
26. Способ по п.24 или 25, где указанный TRP-каналообразующий рецептор активируется экзогенным или эндогенным агонистом.
27. Способ по п.25 или 26, где указанным TRP-каналообразующим рецептором является TRPA1 или TRPV1.
28. Способ по п.27, где указанное соединение способно проникать в ноцицепторы или прурицепторы через указанный рецептор TRPA1 или TRPV1, когда указанный рецептор активирован.
29. Способ по п.24, где указанное соединение ингибирует потенциалзависимые натриевые каналы.
30. Способ по п. 24, где указанная боль выбрана из группы, состоящей из нейропатической боли, воспалительной боли, ноцицептивной боли, боли, вызванной инфекцией и боли во время процедуры.
31. Способ по п.24, где указанное нейрогенное воспалительное заболевание выбрано из группы, состоящей из аллергического воспаления, астмы, хронического кашля, конъюнктивита, ринита, псориаза, воспалительного заболевания кишечника и интерстициального цистита, атопического дерматита.
32. Способ по п.24, где указанная композиция содержит четвертичное аминное соединение, выбранное из группы, состоящей из:
(Соединение 6)
Figure 00000008
, (Соединение 3)
Figure 00000009
, (Соединение 14)
Figure 00000010
и (Соединение21)
Figure 00000011
.
RU2018107695A 2015-08-03 2016-08-03 Заряженные блокаторы ионных каналов и способы их применения RU2018107695A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562200205P 2015-08-03 2015-08-03
US62/200,205 2015-08-03
PCT/US2016/045354 WO2017024037A1 (en) 2015-08-03 2016-08-03 Charged ion channel blockers and methods for use

Publications (2)

Publication Number Publication Date
RU2018107695A true RU2018107695A (ru) 2019-09-05
RU2018107695A3 RU2018107695A3 (ru) 2020-01-13

Family

ID=57943976

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018107695A RU2018107695A (ru) 2015-08-03 2016-08-03 Заряженные блокаторы ионных каналов и способы их применения

Country Status (11)

Country Link
US (3) US11021443B2 (ru)
EP (1) EP3331609A4 (ru)
JP (2) JP6833811B2 (ru)
KR (1) KR20180069782A (ru)
CN (1) CN108348774A (ru)
AU (1) AU2016301282B2 (ru)
CA (1) CA2994545A1 (ru)
IL (1) IL257326A (ru)
MX (1) MX2018001447A (ru)
RU (1) RU2018107695A (ru)
WO (1) WO2017024037A1 (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6205133B2 (ja) 2009-07-10 2017-09-27 プレジデント アンド フェローズ オブ ハーバード カレッジ 抗炎症剤としての恒久的に荷電したナトリウムおよびカルシウムチャンネルブロッカー
RU2018107695A (ru) 2015-08-03 2019-09-05 Президент Энд Феллоуз Оф Гарвард Колледж Заряженные блокаторы ионных каналов и способы их применения
EP3825311A4 (en) * 2018-07-19 2022-08-31 Jiangsu Hengrui Medicine Co., Ltd. METHOD OF PREPARING A COAGAGING FACTOR XIA INHIBITOR AND INTERMEDIATE THEREOF
WO2020142657A1 (en) * 2019-01-03 2020-07-09 President And Fellows Of Harvard College Charged ion channel blockers and methods for use thereof
US10927096B2 (en) * 2019-03-11 2021-02-23 Nocion Therapeutics, Inc. Ester substituted ion channel blockers and methods for use
KR20210145166A (ko) 2019-03-11 2021-12-01 녹시온 테라퓨틱스 인코포레이티드 하전된 이온 채널 차단제 및 사용 방법
US10780083B1 (en) 2019-03-11 2020-09-22 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US10828287B2 (en) 2019-03-11 2020-11-10 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US10934263B2 (en) 2019-03-11 2021-03-02 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
CA3155805A1 (en) * 2019-11-06 2021-05-14 Nocion Therapeutics, Inc. Phosphonium ion channel blockers and methods for use
US10933055B1 (en) 2019-11-06 2021-03-02 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
JP2022554359A (ja) 2019-11-06 2022-12-28 ノシオン セラピューティクス，インコーポレイテッド ホスホニウムイオンチャンネル遮断薬および使用方法
US10842798B1 (en) 2019-11-06 2020-11-24 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US12162851B2 (en) 2020-03-11 2024-12-10 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
CN119118953A (zh) 2020-03-11 2024-12-13 诺西恩医疗公司 带电的离子通道阻滞剂及其使用方法
CN113214107B (zh) * 2020-05-11 2022-03-18 四川道珍科技有限公司 一种芳香类化合物、制备方法及在药物中的应用
WO2024151802A2 (en) * 2023-01-12 2024-07-18 President And Fellows Of Harvard College Methods and compositions for treating or preventing itch
WO2024184543A1 (en) * 2023-03-08 2024-09-12 Johann Wolfgang Goethe-Universität Frankfurt am Main Slack-activating compounds and their medical use
EP4428132A1 (en) * 2023-03-08 2024-09-11 Johann-Wolfgang-Goethe-Universität Frankfurt am Main Slack-activating compounds and their medical use

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE150423C (ru)
DE151036C (ru)
US812554A (en) 1905-11-08 1906-02-13 Hoechst Ag Alkamin esters of para-aminobenzoic acid.
US1889645A (en) 1930-12-22 1932-11-29 Winthrop Chem Co Inc Beta-dimethylaminoethyl ester of para-butylamino-benzoic acid
US2441498A (en) 1943-07-15 1948-05-11 Astra Apotekarnes Kem Fab Alkyl glycinanilides
US2689248A (en) 1950-06-17 1954-09-14 Sterling Drug Inc Tertiary-aminoalkyl 4-amino-2-alkoxybenzoates and their synth esis
US2799679A (en) 1955-04-28 1957-07-16 Bofors Ab Process of preparing amides of heterocyclic carboxylic acids
US2955111A (en) 1957-01-28 1960-10-04 Bofors Ab Synthesis of n-alkyl-piperidine and n-alkyl-pyrrolidine-alpha-carboxylic acid amides
US3160662A (en) 1957-06-26 1964-12-08 Astra Apotekarnes Kem Fab Lower alkylaminoacyl amide anesthetics
GB866604A (en) 1958-05-31 1961-04-26 T & H Smith Ltd New quaternary salts
NL281394A (ru) 1961-07-25
DE1251764B (de) 1965-08-18 1967-10-12 C H Boehnnger Sohn Ingelheim/ Rhein Verfahren zur Herstellung von antimikrobiell wirksamen 12 3,4-Tetra hydro 9 -ammo acridmiumverbmdungen
US3812147A (en) 1970-12-22 1974-05-21 Astra Pharma Prod Acylxylidide local anaesthetics
US3931195A (en) 1971-03-03 1976-01-06 Mead Johnson & Company Substituted piperidines
BE786875A (fr) 1971-07-28 1973-01-29 Astra Pharma Prod Amide, methode pour sa preparation et ses compositions therapeutiques
US3773939A (en) 1971-11-24 1973-11-20 Janssen Pharmaceutica Nv N-arallyl-n'-aralkyl piperazine pharmaceutical compositions
US4069309A (en) 1972-09-19 1978-01-17 Avon Products, Inc. Cationic skin substantive sunscreen composition and method
US3900481A (en) 1974-04-01 1975-08-19 Riker Laboratories Inc Derivatives of pyrrolidine and piperidine
CS195321B2 (en) 1975-12-23 1980-01-31 Ciba Geigy Ag Plant growth suppressing agents
US4070347A (en) 1976-08-16 1978-01-24 Alza Corporation Poly(orthoester) co- and homopolymers and poly(orthocarbonate) co- and homopolymers having carbonyloxy functionality
SE7713618L (sv) 1977-12-01 1979-06-02 Astra Laekemedel Ab Lokalanestetisk blandning
DD150423A1 (de) * 1979-03-02 1981-09-02 Alfred Barth Wachstumsregulatoren
DE2915250A1 (de) 1979-04-14 1980-10-30 Basf Ag Salze von alpha -aminoacetaniliden
US4293539A (en) 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
US4877805A (en) 1985-07-26 1989-10-31 Kligman Albert M Methods for treatment of sundamaged human skin with retinoids
US4757128A (en) 1986-08-01 1988-07-12 Massachusetts Institute Of Technology High molecular weight polyanhydride and preparation thereof
US5169637A (en) 1983-03-24 1992-12-08 The Liposome Company, Inc. Stable plurilamellar vesicles
CA1237671A (en) 1983-08-01 1988-06-07 Michael W. Fountain Enhancement of pharmaceutical activity
DE3379266D1 (en) 1983-08-01 1989-04-06 Astra Laekemedel Ab L-n-n-propylpipecolic acid-2,6-xylidide and method for preparing the same
US4975282A (en) 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
US5409704A (en) 1985-06-26 1995-04-25 The Liposome Company, Inc. Liposomes comprising aminoglycoside phosphates and methods of production and use
US5023087A (en) 1986-02-10 1991-06-11 Liposome Technology, Inc. Efficient method for preparation of prolonged release liposome-based drug delivery system
IE60901B1 (en) 1986-08-21 1994-08-24 Vestar Inc Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics
US5049388A (en) 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
US5032582A (en) 1987-02-27 1991-07-16 Liposome Technology, Inc. Method for treating fungal infections with amphotericin B/cholesterol sulfate composition
US4994213A (en) 1988-05-17 1991-02-19 Liposome Technology, Inc. Method of preparing lipid structures
US5082866A (en) 1988-06-01 1992-01-21 Odontex, Inc. Biodegradable absorption enhancers
US4980378A (en) 1988-06-01 1990-12-25 Odontex, Inc. Biodegradable absorption enhancers
US5194581A (en) 1989-03-09 1993-03-16 Leong Kam W Biodegradable poly(phosphoesters)
US5194266A (en) 1989-08-08 1993-03-16 Liposome Technology, Inc. Amphotericin B/cholesterol sulfate composition and method
US5356633A (en) 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
ATE139439T1 (de) 1991-04-19 1996-07-15 Nexstar Pharmaceuticals Inc Pharmazeutische formulierung und pharmazeutisches verfahren
US5176907A (en) 1991-08-13 1993-01-05 The Johns Hopkins University School Of Medicine Biocompatible and biodegradable poly (phosphoester-urethanes)
GR1002207B (en) 1992-08-06 1996-03-27 Johnson & Johnson Consumer Skin care compositions containing imidazoles.
US5552155A (en) 1992-12-04 1996-09-03 The Liposome Company, Inc. Fusogenic lipsomes and methods for making and using same
US5480971A (en) 1993-06-17 1996-01-02 Houghten Pharmaceuticals, Inc. Peralkylated oligopeptide mixtures
US6051576A (en) 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
US5591317A (en) 1994-02-16 1997-01-07 Pitts, Jr.; M. Michael Electrostatic device for water treatment
US5716622A (en) 1995-01-06 1998-02-10 The Rockefeller University Functionally active regions of signal transducer and activators of transcription
US5783683A (en) 1995-01-10 1998-07-21 Genta Inc. Antisense oligonucleotides which reduce expression of the FGFRI gene
US5747470A (en) 1995-06-07 1998-05-05 Gen-Probe Incorporated Method for inhibiting cellular proliferation using antisense oligonucleotides to gp130 mRNA
AU5938996A (en) 1995-06-07 1996-12-30 Nexstar Pharmaceuticals, Inc. Method for encapsulating pharmaceutical materials
US6413961B1 (en) 1995-12-12 2002-07-02 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
SE508357C2 (sv) 1996-01-02 1998-09-28 Kay Laserow Mätinstrument för mätning av smärta jämte ett förfarande för att med ett mätinstrument mäta smärta
WO1998024428A1 (en) * 1996-12-02 1998-06-11 Brigham & Women's Hospital, Inc. Long-acting local anesthetics
SE9604751D0 (sv) 1996-12-20 1996-12-20 Astra Ab New therapy
US5837713A (en) 1997-02-26 1998-11-17 Mayo Foundation For Medical Education And Research Treatment of eosinophil-associated pathologies by administration of topical anesthetics and glucocorticoids
ATE216712T1 (de) 1997-06-18 2002-05-15 Guilford Pharm Inc Zweistufige lösungspolymerisation von hochmolekularen poly(phosphorestern)
US6028163A (en) 1997-06-27 2000-02-22 Guilford Pharmaceuticals Inc. Solution polymerization of high molecular weight poly(phosphoesters) in toluene
ATE320249T1 (de) 1997-07-08 2006-04-15 Ono Pharmaceutical Co Aminosäurederivate
US6623040B1 (en) 1997-09-03 2003-09-23 Recot, Inc. Method for determining forced choice consumer preferences by hedonic testing
TW536401B (en) 1997-09-03 2003-06-11 Cardiome Pharma Corp A pharmaceutical composition of N,N-bis(phenylcarbamoylmethyl)dimethylammomum chloride and derivatives for the treatment of pain
US6083996A (en) 1997-11-05 2000-07-04 Nexmed Holdings, Inc. Topical compositions for NSAI drug delivery
US6362197B1 (en) 1998-06-09 2002-03-26 Cardiome Pharma Corp. Compositions and method for treatment of cough
JP2000143635A (ja) 1998-06-10 2000-05-26 Takeda Chem Ind Ltd 血管新生阻害剤
US6153212A (en) 1998-10-02 2000-11-28 Guilford Pharmaceuticals Inc. Biodegradable terephthalate polyester-poly (phosphonate) compositions, articles, and methods of using the same
US7507545B2 (en) 1999-03-31 2009-03-24 Cardiome Pharma Corp. Ion channel modulating activity method
US6103255A (en) 1999-04-16 2000-08-15 Rutgers, The State University Porous polymer scaffolds for tissue engineering
US6118020A (en) 1999-05-19 2000-09-12 Nexmed Holdings, Inc. Crystalline salts of dodecyl 2-(N,N-dimethylamino)-propionate
EP1216242A1 (en) 1999-10-01 2002-06-26 Advanced Medicine, Inc. Macrocyclic quinazolinones and their use as local anesthetics
HUP0301686A2 (hu) 1999-12-15 2003-08-28 Ucb Farchim S.A. Ciklikus kvaterner ammóniumvegyületek alkalmazása köhögés elleni gyógyszerkészítmények előállítására
JP2003516982A (ja) 1999-12-15 2003-05-20 ユーシィービィ ファルチム ソシエテアノニム 医薬品としてのｎ−置換環状または非環状アミン類の４級塩
AU3162001A (en) 1999-12-21 2001-07-03 Id-Pharma Gmbh Medicament, a method for its production and the use thereof
US20050009016A1 (en) 2000-05-04 2005-01-13 Moskowitz David W. Tgfbeta-rII promoter polymorphisms
JP2004501193A (ja) 2000-06-23 2004-01-15 マヨ　ファウンデーション　フォー　メディカル　エデュケーション　アンド　リサーチ 局所麻酔薬を用いる好中球関連疾患を処置する方法
DE10039449A1 (de) 2000-08-11 2003-07-24 Id Pharma Gmbh I Ins Verwendung einer lokalanästhetikumhaltigen Zusammensetzung zur Behandlung von Hyperalgesien
US6766319B1 (en) 2000-10-31 2004-07-20 Robert J. Might Method and apparatus for gathering and evaluating information
US6884782B2 (en) 2000-11-08 2005-04-26 Amgen Inc. STAT modulators
JP2004521111A (ja) 2001-01-25 2004-07-15 ユーロ−セルティーク，エス．エイ． 局所麻酔薬および使用法
US20040146590A1 (en) 2001-03-22 2004-07-29 Iadarola Michael J Molecular neurochirurgie for pain control administering locally capsaicin or resinferatoxin
US20030027833A1 (en) 2001-05-07 2003-02-06 Cleary Gary W. Compositions and delivery systems for administration of a local anesthetic agent
MXPA03011652A (es) 2001-06-15 2004-05-31 Vertex Pharma 5-(2-aminopirimidin-4-il) benzioxazoles como inhibidores de proteinas cinasa.
ITMI20012025A1 (it) * 2001-09-28 2003-03-28 Dompe Spa Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono
US7585511B2 (en) 2002-08-02 2009-09-08 Universite Libre De Bruxelles Apolipoprotein L-I and/or derivated polypeptide for the treatment of and/or the prevention of diseases induced by trypanosoma
AU2003286757B2 (en) 2002-11-01 2009-06-04 Merck Sharp & Dohme Corp. Carbonylamino-benzimidazole derivatives as androgen receptor modulators
EA012599B1 (ru) 2003-04-10 2009-10-30 Ньюроджескс, Инк. Способы и композиции для введения агонистов trpv1
US20040220187A1 (en) 2003-04-22 2004-11-04 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of pain, inflammation or inflammation mediated disorders
ES2223277B1 (es) 2003-06-19 2006-03-01 Fernando Bouffard Fita Composicion anestesica para administracion topica.
WO2005014849A2 (en) 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
US8361467B2 (en) 2003-07-30 2013-01-29 Depuy Spine, Inc. Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
NO20034069L (no) 2003-09-12 2005-03-14 Aximed As Fremstilling og bruk av capsaicinderivater
US20070149469A1 (en) 2003-10-02 2007-06-28 Christian Korherr Medical use of tbk-1 or of inhibitors thereof
US20050142596A1 (en) 2003-11-14 2005-06-30 Krolewski Andrzej S. Methods of diagnosing renal and cardiovascular disease
MXPA06006460A (es) 2003-12-11 2006-08-23 Univ Texas Compuestos para el tratamiento de enfermedades proliferativas celulares.
WO2005089206A2 (en) 2004-03-13 2005-09-29 Irm Llc Modulators of ion channel trpa1
US7161034B2 (en) * 2004-04-20 2007-01-09 Dade Behring Inc. Lidocaine analogs and methods of making and using same
WO2005105814A1 (en) 2004-04-28 2005-11-10 Incyte Corporation Tetracyclic inhibitors of janus kinases
WO2005117981A1 (en) 2004-06-02 2005-12-15 Sri International Formulations comprising a capsaicinoid a local anesthetic and/or an antipruritic agent for the treatment of pain
MX2007000793A (es) 2004-07-24 2007-03-21 Esteve Labor Dr Uso de compuestos activos sobre el receptor sigma para el tratamiento de alodinia mecanica.
ITMI20041566A1 (it) 2004-07-30 2004-10-30 Indena Spa "trpv1 agonisti, formulazioni che li contengono e loro usi"
JP2008513445A (ja) 2004-09-20 2008-05-01 コラス ファーマ インコーポレイテッド 吸入による送達で治療効果のある薬剤の許容性の改善方法
US7947682B2 (en) 2004-12-29 2011-05-24 University Of Southern California Substituted N′-pyrrolo[1,2-a]quinoxalin-4-yl-hydrazides as anti-cancer agents
AU2005316687B2 (en) 2004-12-16 2008-06-26 Alkermes, Inc. Compositions and methods for pulmonary conditions
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
WO2006133588A1 (en) 2005-06-13 2006-12-21 Oncalis Ag ARYL UREA COMPOUNDS AS β-SECRETASE INHIBITORS
US20070149506A1 (en) 2005-09-22 2007-06-28 Arvanitis Argyrios G Azepine inhibitors of Janus kinases
AU2006304205C1 (en) 2005-10-12 2012-11-15 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
SI1966202T1 (sl) 2005-12-13 2012-01-31 Incyte Corp S heteroarilom substituirani pirolo (2,3-b)piridini in pirolo (2,3-b)pirimidini kot zaviralci janus kinaze
US20070197509A1 (en) 2005-12-21 2007-08-23 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
EP1867338A1 (en) 2006-05-30 2007-12-19 Université Libre De Bruxelles Pharmaceutical composition comprising apolipoproteins for the treatment of human diseases
CA2668652C (en) 2006-11-20 2018-06-12 President And Fellows Of Harvard College Inhibitors of voltage-gated ion channels for use in treating pain and pruritis
CN107469085A (zh) * 2006-11-20 2017-12-15 哈佛大学校长及研究员协会 治疗疼痛和瘙痒的方法、组合物和试剂盒
EP2121692B1 (en) 2006-12-22 2013-04-10 Incyte Corporation Substituted heterocycles as janus kinase inhibitors
US7705004B2 (en) 2007-08-17 2010-04-27 Portola Pharmaceuticals, Inc. Protein kinase inhibitors
CN101156851A (zh) 2007-09-27 2008-04-09 刘全胜 盐酸尼卡地平分散片及其制备方法
WO2009114139A2 (en) 2008-03-11 2009-09-17 President And Fellows Of Harvard College Methods, compositions, and kits for treating pain and pruritis
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
EP2271631B1 (en) 2008-04-22 2018-07-04 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
ES2521676T3 (es) 2008-07-08 2014-11-13 Board Of Regents, The University Of Texas System Nuevos agentes inhibidores de la proliferación y de la activación de transductores de señales y activadores de la transcripción (STATS)
DE102008037682A1 (de) 2008-08-14 2010-04-08 Strackharn, Klaus, Dr.med. Verwendung äquipotenter Dosierungen von Lokalanästetika oder Derivaten davon zur Therapie chronischer Schmerzen
CN101347427A (zh) 2008-09-22 2009-01-21 北京理工大学 一种沙坦化合物或其可药用盐和钙通道阻断剂或可药用盐的复方
CL2009001884A1 (es) 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
EP3087988A3 (en) 2008-10-06 2017-03-01 Idera Pharmaceuticals, Inc. Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto
US9278134B2 (en) 2008-12-29 2016-03-08 The Board Of Trustees Of The University Of Alabama Dual functioning ionic liquids and salts thereof
EP2411019A2 (en) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP6205133B2 (ja) 2009-07-10 2017-09-27 プレジデント アンド フェローズ オブ ハーバード カレッジ 抗炎症剤としての恒久的に荷電したナトリウムおよびカルシウムチャンネルブロッカー
US9023355B2 (en) 2010-04-13 2015-05-05 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for treating renal disease
WO2011133474A2 (en) 2010-04-18 2011-10-27 Beth Israel Deaconess Medical Center Methods of predicting predisposition to or risk of kidney disease
US20130225578A1 (en) 2010-09-01 2013-08-29 Ambit Biosciences Corporation 7-cyclylquinazoline derivatives and methods of use thereof
WO2013130808A1 (en) 2012-02-29 2013-09-06 D.E. Shaw Research, Llc Methods for screening voltage gated proteins
WO2014025761A1 (en) 2012-08-07 2014-02-13 Children's Medical Center Corporation Methods to treat neurodegenerative diseases
US8822537B2 (en) 2012-09-27 2014-09-02 Achelios Therapeutics, Inc. Topical ketoprofen composition
RU2018107695A (ru) 2015-08-03 2019-09-05 Президент Энд Феллоуз Оф Гарвард Колледж Заряженные блокаторы ионных каналов и способы их применения
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
CN108929263B (zh) 2017-05-26 2022-07-22 中国医学科学院药物研究所 芳酰胺类Kv2.1抑制剂及其制备方法、药物组合物和用途
WO2020142657A1 (en) 2019-01-03 2020-07-09 President And Fellows Of Harvard College Charged ion channel blockers and methods for use thereof

Also Published As

Publication number Publication date
EP3331609A1 (en) 2018-06-13
MX2018001447A (es) 2019-02-21
JP2018530518A (ja) 2018-10-18
EP3331609A4 (en) 2019-03-27
US20180237392A1 (en) 2018-08-23
US11021443B2 (en) 2021-06-01
CA2994545A1 (en) 2017-02-09
US20220041552A1 (en) 2022-02-10
CN108348774A (zh) 2018-07-31
AU2016301282B2 (en) 2022-03-17
AU2016301282A1 (en) 2018-03-29
WO2017024037A1 (en) 2017-02-09
IL257326A (en) 2018-03-29
US20200377459A1 (en) 2020-12-03
RU2018107695A3 (ru) 2020-01-13
KR20180069782A (ko) 2018-06-25
JP2021075546A (ja) 2021-05-20
JP6833811B2 (ja) 2021-02-24
WO2017024037A8 (en) 2017-05-11

Similar Documents

Publication Publication Date Title
RU2018107695A (ru) Заряженные блокаторы ионных каналов и способы их применения
RU2008129638A (ru) Производные пиразина в качестве блокатора эпителиального натриевого канала
SI2961736T1 (en) Histone demethylase inhibitors
CA2722776A1 (en) Nmda receptor antagonists for the treatment of neuropsychiatric disorders
RU2011121567A (ru) Изоиндолиновые соединения для применения при лечении рака
AR078508A1 (es) Derivados spiro [2.4]heptano puenteados, composiciones farmaceuticas y uso de los mismos
RU2013144215A (ru) Средство для борьбы с эндопаразитами
DE69833748T2 (de) Benzocycloheptha-thiophen verbindungen
EP1794154B1 (de) Heteroarylverbindungen als betamimetkia zur behandlung von atemwegserkrankungen
AU782816B2 (en) Optically active isomers of ketotifen and therapeutically active metabolites thereof
RU2014138827A (ru) Антагонисты рецептора андрогена и их применение
JP2002535323A5 (ru)
NO20054206L (no) Bifenylderivater
JP2005539012A5 (ru)
RU2008143557A (ru) Тиазолилдигидроиндазолы
US20140275016A1 (en) N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities
RU2015101532A (ru) Замещенные бициклические алкокси-пиразольные аналоги в качестве аллостерических модуляторов рецепторов mglur5
RU2014144951A (ru) Новое 1-замещенное производное индазола
JP2017522304A5 (ru)
RU2011147186A (ru) 2, 5-дизамещенные арилсульфонамидные антагонисты ссr3
RU2007144988A (ru) Производные 4-фенил-5-оксо-1, 4, 5, 6, 7, 8-гексагидрохинолина в качестве лекарственных средств для лечения бесплодия
RU2007130144A (ru) Гетероциклические соединения в качестве антагонистов cccr2b
DE602004006997T2 (de) 4-(aminomethyl)-piperidinbenzamide als 5ht4 -antagonisten
JP2012530061A (ja) イミノ糖ならびにブニヤウイルスおよびトガウイルス疾患を治療する方法
RU2015148927A (ru) Производные изохинолина, стимулирующие нейрогенез

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20201026

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载